Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v7-EN | Version v5-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2021-10-20 | 2021-09-08 |
| Drug Identification Number | 02483327 | 02483327 |
| Brand name | ACTEMRA | ACTEMRA |
| Common or Proper name | ACTEMRA | ACTEMRA |
| Company Name | HOFFMANN-LA ROCHE LIMITED | HOFFMANN-LA ROCHE LIMITED |
| Ingredients | TOCILIZUMAB | TOCILIZUMAB |
| Strength(s) | 162MG | 162MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | SUBCUTANEOUS SUBCUTANEOUS | SUBCUTANEOUS SUBCUTANEOUS |
| Packaging size | Autoinjector | Autoinjector |
| ATC code | L04AC | L04AC |
| ATC description | IMMUNOSUPPRESSANTS | IMMUNOSUPPRESSANTS |
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | 2021-10-31 | 2021-10-20 |
| Actual start date | ||
| Estimated end date | 2021-12-31 | 2021-12-31 |
| Actual end date | ||
| Shortage status | Anticipated shortage | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | During the COVID-19 pandemic, the demand for Actemra has been increasing at a global level. Roche has started to apply mitigation strategies to support our efforts to increase the supply of Actemra. | During the COVID-19 pandemic, the demand for Actemra has been increasing at a global level. Roche has started to apply mitigation strategies to support our efforts to increase the supply of Actemra. |
| Health Canada comments |